chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On evening of vaccine, he began to run high fever of 101.5. next day 102. 3 with extended chills, Doctor was called and patient was told to take Tylenol, On second time Doctor was called, he was told to alternate Tylenol with ibuphrofen. Fever came down on 2/28 started back up on 3/2 , went to Er ON 3/4 FOR BREATHING ISSUES, a blood infection was found, went back to ER ON 3/8  FOR ANTIBIOTIC,( DOCTOR HAD WANTED HIM ADMITTED,THIS WAS NOT COMMUNICATED) , next day was admitted to Providence Hospital for IV  antibiotics, dismissed from Providence on 3/13, with antibiotics infusion to continue at home.
presented 48 hours after booster vaccination with encephalopathy and stress/takatsubo cardiomyopathy
soreness in her left arm; little general soreness, body pain (not crucial, not really bad); This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (soreness in her left arm) and MYALGIA (little general soreness, body pain (not crucial, not really bad)) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jul-2021, the patient experienced PAIN IN EXTREMITY (soreness in her left arm) and MYALGIA (little general soreness, body pain (not crucial, not really bad)). The patient was treated with DIPHENHYDRAMINE, PARACETAMOL (EXTRA STRENGTH TYLENOL PM) ongoing since an unknown date for Adverse event, at an unspecified dose and frequency and IBUPROFEN (ADVIL 12 HOUR) ongoing since an unknown date for Adverse event, at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (soreness in her left arm) and MYALGIA (little general soreness, body pain (not crucial, not really bad)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported.  Treatment medications was not provided by the reporter
Patient received Pfizer COVID-19 vaccine on 3/28/2021 and 4/19/2021. On 10/25/21, patient admitted to our facility for acute hypoxic respiratory failure due to COVID-19 pneumonia. Patient received a dose of tocilizumab on 10/27/21 and receiving dexamethasone. During admission, patient also newly diagnosed with DM2 (A1C 10.3). As of today (11/1/21), patient is still admitted in the med/surg unit.
rundown, fatique; joint paint; tingling in legs and feet; foot pain; swelling in the injection site; arm pain; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date in Apr2021(at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food, or other products. It was not reported whether the patient received any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced rundown, fatigue (reported as fatique), joint paint, tingling in legs and feet, foot pain, swelling in the injection site, arm pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. It was unknown whether therapeutic measures were taken as a result of the events. The clinical outcome of the events rundown, fatigue (reported as fatique), joint paint, tingling in legs and feet, foot pain, swelling in the injection site, arm pain was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
normally happy pt w/near inconsolability for 4 days beginning shortly p/vax; no fever; pt did devel rash on 30SEP which began fading the next day;
Fever of 103; major body aches; chills; extremely sore arm at injection site for 2 1/2 days
4 days after getting Janssen shot a lump formed at the injection shot and is tender to touch/ slightly sore when untouched - until that time I had no pain, no soreness, no adverse symptoms at all. The lump is still present on day 11 and is still tendor to the touch. I have not seen anyone regarding this adverse effect as I am hoping it eventually goes away.
pt came to pharmacy on 8/31/2023 claiming that she had reaction to the vaccine she got on 8/27/2023 in her right arm. pt received RSV vaccine on her right arm. her arm is still sore and she has pain when she lift her arm. the injection site is feverish and little bit red, it also started bruising . pt tried tylenol and ice pack and that did not help. pt will keep monitoring and contact dr if it gets worse.
03/06/23: Patient was vaccinated with a Shingrix vaccine at Pharmacy. 03/09/23: Patient called Pharmacy to report she had experienced significant redness and pain at the injection site of her Shingrix vaccine. She called her primary care provider whose nurse encouraged her to go to Urgent Care to have her arm looked at. The patient went to Urgent Care and the provider there diagnosed her with cellulitis and prescribed an antibiotic. The patient stated to the pharmacy that the Urgent Care provider told her the vaccine adminstrator had either used a dirty needle or had not cleaned her skin adequately. The patient did start the antibiotic that day and asked the staff pharmacist she was speaking to to have the pharmacy manager call her back to discuss this matter. 03/10/23: I (pharmacy owner / manager) called the patient to discuss. In trying to establish a timeline of events, the patient reported that her pain and redness started within a couple hours after her Shingrix vaccine was administered. She again stated to me that the Urgent Care provider had told her that she had cellulitis and that the vaccine was either given with a dirty needle or inadequate cleaning of her skin prior to immunization. She was prescribed cephalexin 500mg four times daily for 7 days. I did counsel her that Grade 3 injection site reactions can occur in about 1 out of 5 patients who receive a Shingrix vaccine and that the rapid reaction points more towards this than cellulitis. I did, however, tell her that we would certainly defer to the clinical judgment of the Urgent Care provider as he / she examined her and we did not. 03/13/23: I called the Urgent Care to gather additional info to complete this report. I was informed by Urgent Care that they could not share any info with me. They referred me to medical records. I did offer "education" to the Urgent Care nurse about the high incidence of injection site reactions with Shingrix. I called the patient to gather Patient Information for this report. Respectfully, the patient declined to provide additional info, so I recorded as "Unable to Provide." The patient restated her unease about injection technique. I reassured her that we take these matters seriously and we want to gather info and report to VAERS to improve quality. I also reiterated the high incidence of injection site reactions and that the immediate reactions points more towards injection site reaction than cellulitis. I did repeat, though, that we most certainly will defer to the clinical judgment of the Urgent Care provider.
Large rash fitting the description of "Covid Arm" as portrayed in media occurred at injection site one week after the dose was given. Started as small, red bumps and over the next few days became a large, red rash that grew to cover most of the upper arm on the side of the injection site. Rash was itchy with some soreness, but was tolerated with hydrocortisone cream. It took about 7 days for the rash to resolve.
Patient reported soreness in her shoulder/upper arm on Saturday 9/26/15, but that had gone away by her follow up call on Monday 9/28/15.  On 9/26 she noted brownish-green discoloration on the upper left arm where the flu vaccine was administered that was smooth and bruise-like.  She also noticed a rose color farther down her arm towards her elbow.  Denies any itching, hives, bumps, or difficulty breathing.
Information has been received from a health professional concerning a 20 year old healthy female who on 06/11/02 and 07/29/02 was vaccinated with the 1st and 2nd doses of varicella virus vaccine, live. A titer was drawn on 05/19/04, and it was negative for VZVIGG. No other information is available. Unspecified medical attention was sought. There was no product quality complaint. Additional information has been requested.
Hyperventilating, unable to control breathing after 30 min diaphoretic, tingling, cramping hands.
Fever, aches: began at 10 pm the same day of vaccination. The fever and aches responded well to Tylenol. Fever lasted from about 10 pm to 3 pm the following day and then stopped, without the use of medicine. However, the fever and aches later came back that night (3/20, the day after vaccination) at around 10 pm.  Vomiting: Certainly the effect that caught me most off guard. Vomiting lasted from 4:30 pm on 3/20 (day after vaccination) until 7:30 pm that same day. I vomited 5 times in this time span, and was quite nauseous for about an hour or two before the vomiting began. No medicine relieved this effect.  Headache: Came and went with the fever. Not too terrible.  Sore arm: lasted for about 30 hours after the injection.
passed out on day 3 post vaccine; I think I had Guillen Barre; severe muscle weakness of lower extremity; This case was reported by a consumer via interactive digital media and described the occurrence of passed out in a patient who received Herpes zoster (Shingrix) for prophylaxis.   In November 2020, the patient received the 1st dose of Shingrix. On an unknown date, 3 days after receiving Shingrix, the patient experienced passed out (serious criteria GSK medically significant), guillain barre syndrome (serious criteria GSK medically significant) and lower extremities weakness of. On an unknown date, the outcome of the passed out and guillain barre syndrome were unknown and the outcome of the lower extremities weakness of was not recovered/not resolved.   It was unknown if the reporter considered the passed out, guillain barre syndrome and lower extremities weakness of to be related to Shingrix.  Additional details were reported as follows: The patient self-reported this case. The age at vaccination was not reported. The patient passed out on day 3 post vaccine and less than a year after vaccination, then had severe muscle weakness of lower extremity, the patient though he/she had Guillen Barre, the patient's doctor would not listen to him/her. The patient still had leg weakness this far out. The patient asked would it get better. The follow-up would not possible as no contact details were available.
This spontaneous report as received from a certified medical assistant refers to multiple unspecified patients of unknown age and gender. The patients' concurrent conditions, medical history and concomitant medications were not reported. On unknown dates, the patients were vaccinated with improperly stored VARIVAX lot # L039092, expiry date 06-OCT-2017, lot # L043622, expiry date 03-NOV-2017, lot # M004326, expiry date 25-JAN-2018 (dose, route and site of administration were not reported). There were no known adverse effects. The vaccines experienced temperature excursion of -5.2 degrees Celsius for 50 hours 17 minutes. This is one of several reports received from the same source. Follow up information has been received from a certified medical assistant on 30-AUG-2016. The nurse reported that the specified lot numbers of improperly stored vaccines administered between 19-MAY-2016 to 01-JUL-2016 were not available. This report refers to a patient of unknown age and gender. On 23-JUN-2016, the patient was vaccinated with incorrectly stored ROTATEQ orally, lot # L035511 or K022993 or L029618. Additional information has been requested.
Muscles aches Upset stomach Extreme fatigue Chest discomfort and heaviness Sore throat Sinus infection Went to Urgent care on 3-25-2021 and put on antibiotic
A patient was administered an expired dose of the Modena COVID-19 vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (A patient was administered an expired dose of the Modena COVID-19 vaccine) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011F21A) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (A patient was administered an expired dose of the Modena COVID-19 vaccine). On 10-Nov-2021, EXPIRED PRODUCT ADMINISTERED (A patient was administered an expired dose of the Modena COVID-19 vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Pharmacist stated that vials were arrived on 01-OCT-2021 and placed in freezer and 2 patients were administered with expired doses on 10-NOV-2021 and mentioned that  vial did not undergo any temperature excursion. No concomitant medications were provided by the reporter. No treatment medications were provided by the reporter.
This spontaneous report was received from a certified medical assistant, referring to a patient of unknown age and gender. The patient concurrent condition and medical history were unknown. On 24-NOV-2015 the patient was vaccinated with an improperly stored dose of M-M-R II (Lot # K024036, expiration date 26-NOV-2016) (dose, administration route and anatomical site of administration were unknown). No concomitant therapies or adverse events were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same source. Additional information has been requested.
Patient with 2 prior Moderna vaccinations who admitted to hospital with encephalopathy and positive COVID PCR.  Provider and d/c summary below:  "61-year-old female history primary lung cancer with metastasis including brain, chronic obstructive pulmonary disease, current nicotine use vaping, daily EtOH use, and steroid induced hyperglycemia presented to the ER on 07/23 for worsening swelling and pain in her right lower extremity.  Prior ER visit 2 days prior, concern cellulitis, started doxycycline and discharge.  RLE swelling did not improve.  She presented to the ER by EMS which found the patient hypotensive in the field with blood pressure 73/50, heart rate 119, and hypoxic 73%....    Disposition:  Patient's current clinical picture appears poor.  Circulatory shock likely multifactorial, will continue volume resuscitation with vasopressor augmentation. S/p 2.6L normal saline from ER. There is concern for severe sepsis with blood cultures pending and broad-spectrum antibiotics started.  Hypoxia is also multifactorial in the setting of metastatic lung disease, chronic obstructive pulmonary disease, and COVID-19 infection.  Her AKI precludes remdesivir use.  Monitor non oliguric AKI, likely circulatory shock/poor RBF vs carboplatin induced in nature.  Patient remains DNR/DNI."  "Upon arrival to the intensive care unit, she became more encephalopathic with increasing O2 needs.  I discussed patient's case with her daughter who is the POA and very clear on her mother's wishes of DNR/DNI status.  The patient initially started on Levophed via MRI port which was being used for chemotherapy.  Most recent chemo 07/20/2022.  She had already received 2.6 L normal saline from the ER and showing significant signs of volume overload though likely remained intravascularly depleted.  This vasoressor was quickly escalated and required addition of vasopressin.  I called the daughter again to inform her that patient was showing signs of multi-system organ failure and clinically declining very rapidly. Advised that she should come to the intensive care unit as soon as possible. She was present with her 2 sons. Patient became more hypotensive, apneic, then passed away"
Left upper arm is very tender, hurts to raise arm up. Mild hear at injection site. Pt applied heart to area, then cool compresses.
A follow up report received 8/14/03 adds: Diagnosed with Lyme disease 8/02 after receiving a full series of Lymerix with titres of 60-70%. Symptoms arthritis and swelling of knees. Lymerix dose #1 6/8/99 Lot #LY123B9. Lymerix dose #2 7/7/99. The medical records state myalgias, knee pain, and lyme disease. As the Lyme disease was diagnosed after all three vaccinations, this might be considered a vaccine failure. However notes found later in the medical records indicate 2 specialists' opinions that the pt had not actually had Lyme disease.  Follow up on 10/16/2003: "Vaccine recipient did not recovere from adverse events.  Same as I reported to you in writing in 07/2003 (3 months ago!).
10NOV95 PM arm sore & hot to touch;11NOV95 AM arm sore, hot to touch @ least 4inches in diameter;12NOV95 arm the same but itched terribly;felt better;13NOV95 arms the same measure 3x3 1/2inch in diameter welt;tx Ibuprofen & DPH, ice;
Pt admitted for encephalopathy, bacterial sepsis with concerns for pneumonia and diabetic hypoglycemia.
Pt w/ hx of allergy to penicillins (rash) & HPV vaccine (unknown reaction).  Pt had syncope, flushing/sweating and dizziness.  BP 119/76, HR 78, RR 18 -- > 107/61, 72, 18.  Recommended to the patient to take 2nd dose supine.  Pt stable and released from the vaccination site.
right deltoid area was raised, swollen, red, and hot to touch. Pt mother treated with benadryl and cold compress. At time of visit area was resolving and no treatment was needed. Total time of healing was 7 days.
On 9/24/2021, I took an at-home COVID test at about 8:30PM, and the result was positive. On the morning of 9/25/2021, I took a rapid test at the ER at a local medical center. Again, the result was positive. It seems that I had a breakthrough case.
didn't sleep; headache; nausea; body ache; chills; rash came back raised up and got a little itchy; raised rash; rash may be a mild case of shingles; This case was reported by a consumer and described the occurrence of shingles in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of rash pruritic (also experienced tingling after receiving 1st dose on 30th August 2020, refer case US2020AMR245204).   On 3rd December 2020, the patient received the 2nd dose of Shingrix. On 3rd December 2020, less than a day after receiving Shingrix, the patient experienced insomnia, headache, nausea, general body pain and chills. In December 2020, the patient experienced shingles, itchy rash and raised rash. The patient was treated with valaciclovir hydrochloride (Valtrex). Rechallenge with Shingrix was positive. On 4th December 2020, the outcome of the insomnia was recovered/resolved. On 6th December 2020, the outcome of the headache, nausea, general body pain and chills were recovered/resolved. On an unknown date, the outcome of the shingles, itchy rash and raised rash were unknown.   It was unknown if the reporter considered the shingles, insomnia, headache, nausea, general body pain, chills, itchy rash and raised rash to be related to Shingrix.  Additional details were reported as follows: The patient did not sleep, headache, nausea, body ache chills lasted till 6th December 2020.  In December 2020, less than a week after receiving Shingrix, her rash came back raised up and got a little itchy.  The rash had never been oozy or blistery and Valtrex makes it decrease in intensity.  In December 2020, less than a week after receiving Shingrix, her general practitioner said the rash might be a mild case of shingles, but she would scheduled for a lyme test next week from day of reporting she may see a dermatologist this friday.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR245204:same reporter
sore arm the next day for 8 days, red patches two days after receiving shot that was there for 8 days, more tired than usual
Pt recvd 3 doses of Hep B vax & on 9APR92 lab eval was neg for Hep B surface antibody; 22APR92 recvd booster dose & exp pain in muscle @ inject site & local flare; also myalgia, arthralgia, flu-like synd & nausea, swelling @ inject site;
Injection site quite sore; body aches; This is a spontaneous report from a contactable consumer (patient).  A 57-year-old male patient received bnt162b2 (BNT162B2), lot number Ez9261, via an unspecified route of administration Left arm from 21Jan2021 09:00 to 21Jan2021 09:00 at SINGLE DOSE (first dose) for COVID-19 immunisation.  Medical history included COVID-19 prior vaccination.  The patient's concomitant medications were not reported.  The patient experienced injection site quite sore and body aches on 22Jan2021 03:00. The outcome of the events was not recovered. The patient was not tested for COVID-19 post vaccination. No treatment was received for the events.
Light headed; Weak; Very sore arm; Headache; Tiredness/Fatigue; Groggy; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW 0172) via an unspecified route of administration in the left arm on an unknown date in Apr2021 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included IgA deficiency, mannose-binding lectin deficiency and COVID-19. The patient had known allergies to penicillin. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included cetirizine hydrochloride (ZYRTEC) from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 09Apr2021 at 12:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Apr2021 at 19:00, the patient experienced very sore arm, headache, tiredness/fatigue, light headed and weak/groggy. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very sore arm, headache, fatigue, light headed and weak/groggy was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
TOOK TWO DOSES IN A ROW; This spontaneous case (PVX2019-1470) was received from a pharmacist on 07-Jun-2019. It describes an 8-year-old male child consumer who "took two doses in a row", while being on oral Vivotif (one capsule every other day) for typhoid prophylaxis.  Case report: The consumer took two doses in a row. The doses were taken on 05-Jun-2019 and 06-Jun-2019, respectively. He had a planned trip on 12-Jun-2019 for 2 months.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event "took two doses in a row" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event "took two doses in a row" was considered as not applicable.